<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614717</url>
  </required_header>
  <id_info>
    <org_study_id>CR-11-030-EU-HF</org_study_id>
    <nct_id>NCT01614717</nct_id>
  </id_info>
  <brief_title>Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY</brief_title>
  <acronym>TRICHAMPION</acronym>
  <official_title>Triple Chamber Pacing in HOCM Patients - TRICHAMPION STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation is a prospective, randomized, single-blinded and multicenter design.

      The purpose of this study is to evaluate the benefit of atrial-synchronous biventricular
      (BiV) pacing in severely symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients
      with severe Left Ventricular Outflow Tract (LVOT) obstruction implanted with a Cardiac
      Resynchronization Therapy - Pacing (CRT-P) device.

      Randomization

        -  Implant will be performed (CRT-P).

        -  Patients will be randomized 1:1 to either Treatment Group (Optimized Biventricular (DDD)
           pacing) or Control Group (Back-up Atrial (AAI) pacing) during the first 12 months:

        -  Treatment Group. The patient´s device is programmed to optimized DDD BiV pacing

        -  Control Group. The patient´s device is programmed to back-up pacing AAI.

        -  After 12 months, the patients initially randomized to the Treatment Group (Optimized DDD
           Pacing) will continue in the same group. The patients initially randomized to Control
           Group (AAI Back-up Pacing) will be changed to the Treatment Group (Optimized DDD
           Pacing). And all the patients will be followed 12 months more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collection

        -  In clinic Follow ups (FU): Enrollment, Baseline, Implant, Pre-discharge, 3 months (M),
           12 M, 15 M and 24 M.

        -  Phone call FU: 6 M, 9 M, 18 M and 21 M.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the percentage of HOCM patients with severe LVOT obstruction implanted with a CRT-P device that have symptomatic improvement at 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint of the study is to evaluate the percentage of HOCM patients with severe LVOT obstruction implanted with a CRT-P device that have symptomatic improvement at 12 months post-implant.
The symptomatic improvement is a combined endpoint defined as:
An improvement of at least one New Yorl Heart Association (NYHA) functional class and
An improvement of 10 points in the Quality of Life (QoL) Questionnaire score and
An increase &gt;10% in bike exercise time in the steady state Cardiopulmonary Exercise Test (CPET).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertrophic Cardiomyopathy With Obstruction</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-P Implant</intervention_name>
    <description>All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unequivocal diagnosis of hypertrophic cardiomyopathy (HCM), on the basis of
             2-dimensional echocardiographic demonstration of a hypertrophied (wall thickness ≥15
             mm) and nondilated Left Ventricle (Left Ventricle End Diastolic Diameter (LVEDD) &lt;
             55mm) confirmed by a Core Lab Echo (Appendix I).

          2. Significant resting (not provoked) LV outflow tract obstruction, on the basis of peak
             LVOT gradient ≥50 mmHg, estimated by continuous wave Doppler and confirmed by a Core
             Lab Echo (Appendix I).

          3. Presence of refractory symptoms (exertional dyspnea or chest pain) despite of optimal
             treatment with betablockers and/or verapamil for at least 3 months (NYHA class &gt;II).

          4. Patients that refuse or have contraindication for septal myectomy or septal ablation
             (i.e., comorbidity, inappropriate coronary anatomy for septal ablation), that prefer
             cardiac pacing, or that are at high risk for developing heart block following septal
             myectomy or septal ablation.

        6. Patient's age is 18 years or greater. 7. Patients must indicate their understanding of
        the study and willingness to participate by signing the appropriate informed consent form.

        8. Patients must be willing and able to comply with all study requirements.

        Exclusion Criteria:

          1. Known causes of cardiac hypertrophy as infiltrative cardiomyopathy, aortic stenosis
             and severe uncontrolled hypertension.

          2. Permanent or persistent atrial fibrillation.

          3. Previous septal myectomy or septal ablation.

          4. Any indication for permanent pacing, except for HOCM.

          5. Any indication for an Implantable Cardioverter Defibrillator (ICD).

          6. Systemic disease that would preclude completion of the protocol.

          7. Any disability or limitations to correctly understand or complete the study (physical,
             intellectual, logistical).

          8. Patients with a life expectancy &lt;24 months (based on investigator assessment).

          9. Patients who are or may potentially be pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Brugada, Proffesor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic I Provincial, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Berruezo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic I Provincial, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Brugada, Proffesor</last_name>
      <phone>(0034) 932 27 54 00</phone>
    </contact>
    <contact_backup>
      <last_name>Antonio Berruezo, Dr.</last_name>
      <phone>(0034) 932 27 54 00</phone>
    </contact_backup>
    <investigator>
      <last_name>Antonio Berruezo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Brugada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertrophic Obstructive Cardiomyopathy</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

